MediWound Ltd. (MDWD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 22 | 24 | 26 | 19 | 20 | 17 | 12 | 24 |
| Operating profit | $m | -25 | -32 | ||||||
| Net profit | $m | -9 | -14 | -20 | -7 | -30 | -24 | -20 | -25 |
| EPS reported | $ | -2.10 | -1.60 | ||||||
| Operating cashflow per share | $ | -1.28 | -1.46 | ||||||
| Capex per share | $ | 0.48 | 0.49 | ||||||
| FCF per share | $ | -1.76 | -1.95 | ||||||
| Free cash flow | $m | -20 | -28 | ||||||
| Net debt | $m | -53 | -34 | ||||||
| Book value equity | $m | 44 | 36 | ||||||
| Book value per share | $ | 3.84 | 2.77 | ||||||
| Number of shares | m | 11.38 | 12.88 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.81 | 5.89 | ||||||
| P/S LTM | x | 12.38 | 17.70 | ||||||
| P/FCF LTM | x | -10.48 | -7.40 | ||||||
| EV/EBITDA LTM | x | -9.94 | -11.23 | ||||||
| EV/Sales LTM | x | 12.58 | 9.51 | ||||||
| Earnings Yield LTM | % | -11.37% | -14.95% | ||||||
| FCF Yield | % | -9.54% | -13.52% | ||||||
| Quality | |||||||||
| ROE | % | -54.73% | -67.22% | ||||||
| ROIC | % | -41.75% | -47.30% | ||||||
| Operating margin | % | -1.49% | -1.94% | ||||||
| Gross margin | % | +19.19% | +19.61% | ||||||
| FCF/Sales | % | -118.14% | -173.57% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -16.14% | -41.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.46 | -2.98 | ||||||
| Net Debt/EBITDA | x | -0.16 | 2.46 | ||||||
| EBIT/Net interest | x | -38.13 | -3.51 | ||||||
| Net debt/market cap | % | 0.00% | +0.53% | ||||||
| Net debt/Equity | x | -1.22 | -0.97 | ||||||
| Gross debt/equity | x | 0.19 | 0.27 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free